# MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

> **NCT01344031** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Estrogen Receptor Positive
- Invasive Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **DRUG:** Anastrozole
- **DRUG:** Fulvestrant
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01344031
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-21
- **Primary completion:** 2011-07-01
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01344031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01344031, "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01344031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*